Defining a new era of oligonucleotides

Defining a new era of oligonucleotides

We are a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases.

Our chemistry platform enables the creation of highly specific, well characterized oligonucleotides designed to deliver superior efficacy and safety across multiple therapeutic modalities. Our pipeline is initially focused on neurological disorders and extends across several other therapeutic areas.

1st

first to design and bring stereopure and allele-specific medicines to clinic

6

neurology development
programs by end of 2018

3

clinical studies
initiated in 2017

5

nucleic acid modalities being advanced with Wave stereopure chemistry

12+

discovery programs

5

therapeutic areas under active investigation

 

Investor Relations

Recent News

May 31, 2018

Wave Life Sciences to Present at the Jefferies 2018 Healthcare Conference

CAMBRIDGE, Mass. , May 31, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that Paul Bolno , M.D., MBA, President and Chief Executive

Events

Recent News

May 31, 2018

Wave Life Sciences to Present at the Jefferies 2018 Healthcare Conference

CAMBRIDGE, Mass. , May 31, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that Paul Bolno , M.D., MBA, President and Chief Executive

Recent News and Events

Copyright Nasdaq. Minimum 15 minutes delayed.